Ovid Therapeutics Inc.
OVID
$2.70
-$0.05-1.82%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 1.58M | 7.12M | 7.25M | 6.61M | 6.65M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.58M | 7.12M | 7.25M | 6.61M | 6.65M |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 1.58M | 7.12M | 7.25M | 6.61M | 6.65M |
| SG&A Expenses | 26.05M | 24.75M | 23.51M | 20.16M | 18.92M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 59.64M | 54.86M | 49.09M | 45.08M | 45.82M |
| Operating Income | -58.06M | -47.74M | -41.84M | -38.47M | -39.17M |
| Income Before Tax | -34.49M | -24.17M | -17.41M | -36.33M | -38.18M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -34.49 | -24.17 | -17.41 | -36.33 | -38.18 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -34.49M | -24.17M | -17.41M | -36.33M | -38.18M |
| EBIT | -58.06M | -47.74M | -41.84M | -38.47M | -39.17M |
| EBITDA | -57.98M | -47.57M | -41.57M | -38.05M | -38.60M |
| EPS Basic | -0.25 | -0.24 | -0.26 | -0.50 | -0.53 |
| Normalized Basic EPS | -0.32 | -0.31 | -0.34 | -0.30 | -0.31 |
| EPS Diluted | -0.25 | -0.24 | -0.26 | -0.50 | -0.53 |
| Normalized Diluted EPS | -0.32 | -0.31 | -0.34 | -0.30 | -0.31 |
| Average Basic Shares Outstanding | 486.41M | 360.07M | 294.94M | 284.28M | 284.14M |
| Average Diluted Shares Outstanding | 486.41M | 360.07M | 294.94M | 284.28M | 284.14M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |